Protocols

As of 2026, no completed randomised controlled trial has evaluated BPC-157 in human orthopaedic surgical populations. Preclinical models consistently show accelerated tendon and ligament repair through fibroblast activation, collagen remodelling, and angiogenesis. A July 2026 narrative review concludes that biological plausibility is established, but the human evidence gap remains the central unresolved barrier to clinical adoption.

The SELECT trial demonstrated that semaglutide 2.4 mg weekly reduced the three-point MACE composite by 20% versus placebo in adults with overweight or obesity and established CVD but without diabetes. The hazard ratio was statistically significant at HR 0·80 and the absolute risk reduction was approximately one and a half percentage points over a mean follow-up of approximately 40 months.

A 2026 review published in Expert Opinion on Drug Delivery (Nayak et al.) synthesises current semaglutide therapy trends and the principal strategies under investigation to overcome its sub-1% oral bioavailability. Subcutaneous formulations remain the clinical gold standard, while SNAC-enabled oral tablets, lipid nanoparticle carriers, and microneedle patch systems represent the leading next-generation delivery approaches.

The FDA's June 2026 wave of 25 warning letters to telehealth companies — combined with its standing position that retatrutide cannot be legally compounded — materially narrows the landscape for practitioners using GLP-1 peptide protocols. Compounded semaglutide and tirzepatide now face tighter sourcing requirements, while retatrutide products outside clinical trials carry no regulatory pathway whatsoever.

Compounded semaglutide occupies an increasingly narrow legal corridor in mid-2026. Bulk shortage-based compounding ended in April–May 2025, the FDA logged more than 1,700 adverse events by May 21, 2026, and on April 30, 2026 proposed excluding semaglutide from the 503B bulks list entirely. A limited patient-specific 503A pathway survives under strict documented-need conditions.

A 2026 review published in International Journal of Molecular Sciences (MDPI) synthesises preclinical evidence showing that BPC-157 — a 15-amino-acid pentadecapeptide derived from human gastric juice — accelerates tissue repair through angiogenesis, collagen synthesis, and FAK-paxillin signalling, while also attenuating pain via nitric oxide pathway modulation and central nociceptive mechanisms.

Animal studies do not confirm that TB-500 directly reactivates dormant tumors in humans, but they raise a biologically credible concern. Preclinical data show that thymosin beta-4 — the endogenous peptide TB-500 mimics — upregulates VEGF, activates pro-invasive signaling in cancer cell lines, and is overexpressed in several human tumor types. No controlled human trial has tested this risk.

PT-141 (bremelanotide) carries a formal FDA contraindication in patients with known cardiovascular disease or uncontrolled hypertension. In controlled trials, the 1.75 mg subcutaneous dose transiently raised mean systolic blood pressure by approximately 3 mmHg and lowered heart rate by roughly 2 bpm — effects that resolve within 12 hours but pose disproportionate risk in patients with compromised cardiac reserve.